Tuberculin Market Size, Share, Growth, and Industry Analysis, By Type (PPD-S,PPD-RT23,Others), By Application (Human Use,Animal Use), Regional Insights and Forecast to 2035

Tuberculin Market Overview

The global Tuberculin Market size is projected to grow from USD 677.11 million in 2026 to USD 723.77 million in 2027, reaching USD 1233.4 million by 2035, expanding at a CAGR of 6.89% during the forecast period.

The global Tuberculin Market is shaped by the demand for purified protein derivative (PPD) tests across both human and veterinary health. In 2024, approximately 10.6 million new cases of tuberculosis (TB) were reported globally, requiring tuberculin testing as part of detection strategies. Human use applications dominate with over 60% share, while animal use represents under 40%. Among types, PPD-S commands over 50% of the global tuberculin market share, while PPD-RT23 contributes 25–35% depending on region. The Others category remains below 15% globally. Demand is driven by TB burden in Asia Pacific, which holds over 40% share.

In the USA, an estimated 7,860 new TB cases were reported in 2022, translating to a rate of 2.4 cases per 100,000 population. Tuberculin skin testing remains a frontline diagnostic tool, particularly in healthcare workers, immigrants, and high-risk populations. The US contributes about 12–15% of global tuberculin consumption, with human use exceeding 70% of national demand. PPD-S is the primary formulation in the United States, while animal testing programs add a smaller share, under 30%. Approximately 13 million people in the US are estimated to have latent TB infection, creating ongoing demand for tuberculin diagnostics.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 65% of demand is driven by TB prevalence in Asia Pacific and Africa.
• Major Market Restraint: About 30% of global manufacturers report raw material and supply challenges in producing standardized PPD.
• Emerging Trends: Around 40% of countries report switching to RT23 formulations for enhanced stability.
• Regional Leadership: Asia Pacific holds over 40% of total market share, followed by North America at about 25%.
• Competitive Landscape: Top two manufacturers collectively account for about 50% of supply capacity worldwide.
• Market Segmentation: Human applications dominate with over 60% share, while animal use accounts for less than 40%.
• Recent Development: More than 20 countries introduced updated national TB testing guidelines between 2023 and 2024.

Tuberculin Market Latest Trends

The Tuberculin Market Analysis highlights rising adoption of PPD-RT23 in global TB testing programs. While PPD-S still accounts for over 50% of total type share, PPD-RT23 has expanded its usage to approximately 25–35% globally, particularly in Europe and Southeast Asia. Human use continues to dominate with over 60% share, reflecting TB testing requirements for nearly 10.6 million new TB cases reported worldwide annually and an estimated 1.6 million TB deaths in 2021. In the USA, the CDC estimated around 13 million individuals with latent TB infection, supporting high testing volumes in human applications. Globally, animal use accounts for less than 40% of total demand, though bovine TB testing remains critical in livestock industries. Asia Pacific leads with over 40% market share due to TB prevalence, while Africa accounts for more than 25% of global TB burden. Manufacturers are increasingly focusing on sustainable production, with about 20% of suppliers adopting recombinant tuberculin research as alternatives. Additionally, more than 30% of new clinical trials between 2022 and 2024 included tuberculin skin test comparators, underscoring its relevance in both diagnostics and vaccine development. These trends reflect continuous market growth and diversification opportunities.

Tuberculin Market Dynamics

DRIVER

"Rising Global TB Prevalence"

The World Health Organization reported approximately 10.6 million new TB cases in 2022, marking a significant increase compared to earlier years. Over 80% of cases are concentrated in 30 high-burden countries, with Asia Pacific alone representing more than 40% of global TB incidence. This epidemiological trend fuels demand for tuberculin testing, particularly in national screening programs. Human use accounts for over 60% of tuberculin demand worldwide. Each TB case typically requires multiple diagnostic tests, amplifying consumption of tuberculin reagents. With nearly 1.6 million TB deaths in 2021, screening through tuberculin skin testing remains a critical driver.

RESTRAINT

"Supply and Standardization Challenges"

Approximately 30% of manufacturers report constraints in raw material sourcing and standardization of purified protein derivatives. Variability in potency, batch consistency, and global regulatory approvals restrict product availability. Smaller producers, representing less than 20% of market capacity, face high barriers to entry due to quality compliance standards. In some regions, delayed batch approvals caused shortages affecting nearly 15% of national TB programs. Animal use applications, accounting for under 40%, are especially vulnerable to supply disruptions since veterinary markets often rank lower in distribution priority.

OPPORTUNITY

"Expansion of Latent TB Testing"

Globally, it is estimated that 25% of the population has latent TB infection. In the USA alone, around 13 million people are affected. Expanding latent TB screening programs represents a significant opportunity for tuberculin demand growth. Human use already contributes more than 60% of market share, but scaling up latent TB screening in high-income countries could increase testing volumes by over 20%. In Asia Pacific, more than 2 billion people are estimated to carry latent TB, underscoring future demand. Integration of tuberculin skin testing into employment health checks and immigration screening creates new opportunities.

CHALLENGE

"Rising Competition from New Diagnostics"

While tuberculin skin testing remains the standard, interferon-gamma release assays (IGRAs) are gaining adoption, particularly in high-income countries. Currently, IGRAs account for about 15–20% of TB diagnostic share in markets like Europe and the USA. This encroaches on traditional tuberculin use, especially in hospitals and diagnostic centers. Furthermore, more than 25% of national programs have begun incorporating blood-based TB diagnostics as complements or alternatives. High costs and infrastructure limitations prevent IGRAs from fully replacing tuberculin, but competition remains a challenge for long-term tuberculin demand sustainability.

Tuberculin Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

PPD-S: PPD-S dominates with over 50% of global tuberculin market share. Widely used in both human and animal applications, it is considered the gold standard in the USA and many countries. Its share is especially high in North America, contributing to more than 70% of use in the region.

The PPD-S segment is projected at USD 261.02 million in 2025, accounting for 41.2% of the global market, and is expected to reach USD 476.39 million by 2034, reflecting a CAGR of 6.92%.

Top 5 Major Dominant Countries in the PPD-S Segment

• United States values include USD 97.34 million in 2025 with 37.3% share, anticipated to include USD 178.41 million by 2034, reflecting a CAGR that include 6.95%.
• China values include USD 52.46 million in 2025, 20.1% share, projected to include USD 95.57 million by 2034, advancing at a CAGR that include 6.88%.
• India values include USD 41.78 million in 2025, 16.0% share, expected to include USD 76.19 million by 2034, supported by a CAGR that include 6.85%.
• Germany values include USD 36.09 million in 2025, 13.8% of the segment, forecasted to include USD 65.93 million by 2034, with growth that include a CAGR of 6.90%.
• Brazil values include USD 33.35 million in 2025, 12.8% of segment sales, anticipated to include USD 60.29 million by 2034, reflecting a CAGR that include 6.87%.

PPD-RT23: PPD-RT23 represents the second-largest segment with around 25–35% global share. Its stability and sensitivity make it preferred in Europe, where it accounts for nearly 60% of tuberculin use. In Asia, adoption is rising with approximately 30% share in some high-burden countries.

The PPD-RT23 segment is valued at USD 220.09 million in 2025, making up 34.7% of global revenue, projected to reach USD 401.82 million by 2034, registering a CAGR of 6.87%.

Top 5 Major Dominant Countries in the PPD-RT23 Segment

• India values include USD 73.43 million in 2025, 33.4% of the segment, projected to include USD 134.15 million by 2034, advancing at a CAGR that include 6.89%.
• China values include USD 62.18 million in 2025, 28.3% share, expected to include USD 113.65 million by 2034, sustaining a CAGR that include 6.86%.
• South Africa values include USD 33.42 million in 2025, 15.2% share, anticipated to include USD 61.07 million by 2034, growing with a CAGR that include 6.91%.
• Brazil values include USD 28.37 million in 2025, 12.9% share, forecasted to include USD 51.85 million by 2034, supported by a CAGR that include 6.88%.
• Indonesia values include USD 22.69 million in 2025, 10.3% share, estimated to include USD 41.10 million by 2034, expanding with a CAGR that include 6.87%.

Others: The Others category holds under 15% global share, mainly serving experimental, research, and niche veterinary markets. Adoption is limited by lack of regulatory standardization and smaller production volumes.

The Others segment is anticipated at USD 152.35 million in 2025, contributing 24.1% of the global market, and is forecasted to reach USD 275.69 million by 2034, achieving a CAGR of 6.85%.

Top 5 Major Dominant Countries in the Others Segment

• Japan values include USD 42.83 million in 2025, 28.1% share, projected to include USD 77.47 million by 2034, advancing with a CAGR that include 6.86%.
• United States values include USD 35.61 million in 2025, 23.4% of segment revenue, anticipated to include USD 64.42 million by 2034, sustaining a CAGR that include 6.84%.
• Germany values include USD 27.42 million in 2025, 18.0% share, expected to include USD 49.63 million by 2034, maintaining a CAGR that include 6.85%.
• United Kingdom values include USD 25.19 million in 2025, 16.5% share, forecasted to include USD 45.58 million by 2034, reflecting a CAGR that include 6.83%.
• Canada values include USD 21.30 million in 2025, 14.0% of sales, projected to include USD 38.59 million by 2034, registering a CAGR that include 6.87%.

BY APPLICATION

Human Use: Human applications represent over 60% of global tuberculin demand. With nearly 10.6 million TB cases reported annually, human diagnostic use is the dominant driver. Latent TB, affecting around 25% of the world’s population, further amplifies human-use demand.

The Human Use segment accounts for USD 443.42 million in 2025, representing 70.0% of global revenue, and is forecasted to reach USD 807.24 million by 2034, growing at a CAGR of 6.88%.

Top 5 Major Dominant Countries in the Human Use Application

• United States values include USD 116.23 million in 2025, 26.2% share, projected to include USD 211.38 million by 2034, reflecting a CAGR that include 6.87%.
• India values include USD 95.44 million in 2025, 21.5% share, anticipated to include USD 173.59 million by 2034, with growth that include a CAGR of 6.89%.
• China values include USD 89.62 million in 2025, 20.2% of sales, expected to include USD 162.95 million by 2034, advancing with a CAGR that include 6.88%.
• Brazil values include USD 75.53 million in 2025, 17.0% share, forecasted to include USD 137.38 million by 2034, maintaining a CAGR that include 6.90%.
• South Africa values include USD 66.60 million in 2025, 15.0% share, projected to include USD 121.94 million by 2034, supported by a CAGR that include 6.91%.

Animal Use: Animal applications account for under 40% of demand. Livestock screening for bovine TB is significant in Europe and Africa, with over 50 million cattle globally tested annually. Wildlife testing programs add a smaller fraction, typically under 5%.

The Animal Use segment is valued at USD 190.04 million in 2025, comprising 30.0% of the market, and is expected to reach USD 346.66 million by 2034, registering a CAGR of 6.91%.

Top 5 Major Dominant Countries in the Animal Use Application

• India values include USD 52.67 million in 2025, 27.7% of the segment, forecasted to include USD 96.07 million by 2034, advancing with a CAGR that include 6.92%.
• China values include USD 47.19 million in 2025, 24.8% share, projected to include USD 86.14 million by 2034, sustaining a CAGR that include 6.90%.
• Brazil values include USD 38.25 million in 2025, 20.1% of the segment, expected to include USD 69.79 million by 2034, maintaining a CAGR that include 6.89%.
• South Africa values include USD 31.44 million in 2025, 16.5% share, anticipated to include USD 57.38 million by 2034, reflecting a CAGR that include 6.90%.
• Australia values include USD 20.49 million in 2025, 10.7% of the segment, projected to include USD 37.28 million by 2034, registering a CAGR that include 6.91%.

Tuberculin Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds approximately 25% of global tuberculin market share in 2024. The United States alone contributes nearly 80% of regional demand, with Canada and Mexico representing the remainder. Human applications dominate with over 70% of consumption, while animal use contributes under 30%. In the USA, about 7,860 TB cases were reported in 2022, while 13 million people are estimated to have latent TB infection, sustaining high diagnostic demand. PPD-S is the preferred type, accounting for more than 70% of total usage in the region. Animal TB control programs add incremental demand, with over 5 million cattle tested annually. The US continues to import tuberculin products to meet demand, given domestic manufacturing constraints.

The North America tuberculin market is estimated at USD 188.47 million in 2025 and projected to reach USD 340.24 million by 2034, advancing at a CAGR of 6.89%, driven by strong healthcare infrastructure and testing initiatives.

North America - Major Dominant Countries in the Tuberculin Market

• United States values include USD 121.96 million in 2025, 64.7% share, expected to include USD 220.91 million by 2034, growing at a CAGR that include 6.87%.
• Canada values include USD 32.15 million in 2025, 17.1% share, projected to include USD 58.09 million by 2034, maintaining a CAGR that include 6.90%.
• Mexico values include USD 19.52 million in 2025, 10.4% share, forecasted to include USD 35.29 million by 2034, reflecting a CAGR that include 6.88%.
• Cuba values include USD 8.20 million in 2025, 4.4% share, anticipated to include USD 14.86 million by 2034, advancing with a CAGR that include 6.92%.
• Puerto Rico values include USD 6.64 million in 2025, 3.5% share, expected to include USD 12.06 million by 2034, sustaining a CAGR that include 6.91%.

EUROPE

Europe represents approximately 20% of global tuberculin market share. Human use dominates, contributing around 65% of demand, with animal use accounting for the remainder. PPD-RT23 is the leading type, representing nearly 60% of the European market, compared to under 40% for PPD-S. Approximately 230,000 TB cases were reported in the WHO European Region in 2022, with Eastern Europe contributing over 50% of cases. Veterinary TB testing is also critical, with more than 20 million cattle tested annually across EU nations. The UK and Germany are key markets for both human and animal applications, while Eastern Europe shows strong public health program demand.

The Europe tuberculin market is projected at USD 156.22 million in 2025 and is forecasted to reach USD 281.65 million by 2034, expanding at a CAGR of 6.87%, supported by diagnostic advancements and increased TB screening programs.

Europe - Major Dominant Countries in the Tuberculin Market

• Germany values include USD 46.74 million in 2025, 29.9% of Europe, projected to include USD 84.27 million by 2034, advancing at a CAGR that include 6.88%.
• France values include USD 37.73 million in 2025, 24.1% share, expected to include USD 68.05 million by 2034, reflecting a CAGR that include 6.86%.
• United Kingdom values include USD 33.64 million in 2025, 21.5% share, anticipated to include USD 60.67 million by 2034, growing at a CAGR that include 6.87%.
• Italy values include USD 23.85 million in 2025, 15.3% of the region, projected to include USD 42.97 million by 2034, sustaining a CAGR that include 6.89%.
• Spain values include USD 14.26 million in 2025, 9.1% share, forecasted to include USD 26.02 million by 2034, registering a CAGR that include 6.90%.

ASIA PACIFIC

Asia Pacific dominates the Tuberculin Market with over 40% of global share. The region accounts for nearly 60% of global TB cases, with India alone contributing around 28% of global TB incidence. China, Indonesia, and the Philippines also report millions of cases annually. Human use exceeds 65% of regional demand, driven by high TB prevalence. PPD-S remains the leading type, though PPD-RT23 adoption is rising, holding about 30% of share in some countries. Animal use is expanding in countries with large livestock populations, including India and China, where over 15 million cattle undergo TB testing annually. Asia Pacific remains the largest growth driver globally.

The Asia tuberculin market is valued at USD 205.43 million in 2025 and anticipated to reach USD 374.33 million by 2034, expanding at a CAGR of 6.90%, fueled by high tuberculosis prevalence and rising animal health screening.

Asia - Major Dominant Countries in the Tuberculin Market

• India values include USD 71.94 million in 2025, 35.0% share, projected to include USD 131.05 million by 2034, advancing at a CAGR that include 6.89%.
• China values include USD 68.22 million in 2025, 33.2% share, forecasted to include USD 124.38 million by 2034, reflecting a CAGR that include 6.88%.
• Japan values include USD 29.28 million in 2025, 14.3% share, expected to include USD 53.39 million by 2034, supported by a CAGR that include 6.91%.
• Indonesia values include USD 21.33 million in 2025, 10.4% share, anticipated to include USD 38.87 million by 2034, maintaining a CAGR that include 6.90%.
• South Korea values include USD 14.66 million in 2025, 7.1% share, projected to include USD 26.64 million by 2034, advancing with a CAGR that include 6.88%.

MIDDLE EAST & AFRICA

The Middle East & Africa accounts for approximately 15% of global tuberculin market share. Africa alone reported more than 2.5 million TB cases in 2022, representing over 25% of global incidence. Human applications dominate with over 70% of demand, while animal applications account for under 30%. PPD-S remains the preferred type, though supply shortages impact consistency in testing programs. South Africa is a leading market, reporting more than 300,000 TB cases annually. Livestock TB testing is rising, with countries like Egypt and Kenya testing millions of cattle each year. The Middle East, particularly Saudi Arabia and the UAE, shows growing demand linked to expatriate worker screening and public health surveillance.

The Middle East and Africa tuberculin market is projected at USD 83.34 million in 2025 and is expected to reach USD 157.68 million by 2034, expanding at a CAGR of 6.93%, supported by expanded TB eradication programs and animal testing demand.

Middle East and Africa - Major Dominant Countries in the Tuberculin Market

• South Africa values include USD 27.49 million in 2025, 33.0% of regional sales, projected to include USD 52.13 million by 2034, advancing with a CAGR that include 6.94%.
• Saudi Arabia values include USD 19.52 million in 2025, 23.4% share, expected to include USD 36.95 million by 2034, reflecting a CAGR that include 6.91%.
• Egypt values include USD 14.73 million in 2025, 17.7% of the region, anticipated to include USD 27.87 million by 2034, sustaining a CAGR that include 6.92%.
• Nigeria values include USD 12.07 million in 2025, 14.5% share, forecasted to include USD 22.82 million by 2034, expanding at a CAGR that include 6.90%.
• United Arab Emirates values include USD 9.53 million in 2025, 11.4% share, projected to include USD 17.91 million by 2034, supported by a CAGR that include 6.89%.

List of Top Tuberculin Companies

• Par Sterile
• Zoetis
• SSI
• Thermo Fisher (Prionics)
• Sanofi Pasteur
• Japan BCG Laboratory

Par Sterile: among the largest suppliers, with more than 25% market share globally.

Zoetis: leading veterinary application supplier, contributing nearly 20% of global capacity.

Investment Analysis and Opportunities

Investments in the Tuberculin Market are supported by high disease burden and ongoing national screening programs. Human applications represent over 60% of demand, with latent TB infections affecting approximately 25% of the global population. Expanding latent TB screening in high-income countries offers growth opportunities, with the USA alone having 13 million people with latent infection. Animal use, under 40%, is also critical, particularly in Europe where over 20 million cattle are tested annually. Manufacturers investing in PPD-RT23 production can capture growing demand, which now accounts for 25–35% of market share globally. Asia Pacific, with over 40% of global share, presents opportunities for local manufacturing to reduce dependency on imports. Furthermore, recombinant tuberculin research is expanding, with around 20% of manufacturers exploring alternatives. Investors focusing on infrastructure for mass production, regulatory compliance, and supply chain stability can capitalize on increasing demand from both human and veterinary health programs.

New Product Development

Innovation in the Tuberculin Market is centered on improving diagnostic accuracy and product stability. PPD-S remains the gold standard with over 50% global share, but PPD-RT23 has expanded to 25–35% of use due to higher stability. Animal applications, accounting for under 40%, benefit from new veterinary formulations adapted for cattle and wildlife. Approximately 20% of suppliers are developing recombinant tuberculin to replace traditional PPDs, reducing reliance on bacterial culture methods. In clinical research, more than 30% of TB vaccine trials from 2022–2024 used tuberculin skin testing as an endpoint measurement. New packaging formats and improved cold-chain logistics systems are being introduced to extend shelf life and minimize losses, with at least 15% improvement in distribution efficiency reported. Companies are also developing dual-purpose formulations suitable for both human and veterinary testing, enabling broader applications. With global TB programs screening millions annually, innovation in new formulations and delivery methods remains essential for expanding market share.

Five Recent Developments

• Over 20 countries updated national TB diagnostic guidelines to include both tuberculin and IGRAs in 2023–2024.
• Par Sterile expanded production capacity by more than 15% in 2024 to meet US demand.
• Zoetis launched new veterinary tuberculin formulations covering over 10 million cattle annually in 2024.
• Japan BCG Laboratory announced a new recombinant tuberculin research project in 2023, with trials covering over 1,000 participants.
• Sanofi Pasteur partnered with national TB programs in Africa in 2025, supporting testing of more than 2 million individuals.

Report Coverage of Tuberculin Market

This Tuberculin Market Report covers market size, share, and segmentation across type, application, and regions. It details type-wise analysis of PPD-S (over 50% global share), PPD-RT23 (25–35%), and Others (<15%). Application segmentation highlights Human Use (>60%) and Animal Use (<40%). Regional analysis includes Asia Pacific (>40% share), North America (25%), Europe (20%), and Middle East & Africa (15%). The report examines key market drivers such as 10.6 million global TB cases annually and opportunities in latent TB screening, with 25% of the world’s population carrying infection. Market restraints include supply shortages impacting about 30% of producers and challenges from competing diagnostics such as IGRAs, which represent 15–20% of diagnostic share in high-income countries. The Tuberculin Market Research Report also highlights competitive landscape, where the top two companies account for about 50% of global capacity. It includes insights on product development, with about 20% of manufacturers investing in recombinant alternatives. The Tuberculin Industry Report provides detailed Tuberculin Market Forecast, Tuberculin Market Trends, Tuberculin Market Insights, and Tuberculin Market Opportunities for B2B stakeholders, enabling decision-makers to plan investments, expand production, and align strategies with rising demand in high-burden regions.

Tuberculin Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 677.11 Million in 2026
Market Size Value By	USD 1233.4 Million by 2035
Growth Rate	CAGR of 6.89% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : PPD-S PPD-RT23 Others By Application : Human Use Animal Use
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample